FXH vs XRAY

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

FXH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FXH entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on FXH as a result. In 77 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for FXH just turned positive on October 14, 2026. Looking at past instances where FXH's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

FXH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FXH crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where FXH advanced for three days, in 238 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XRAY's RSI Oscillator exited the oversold zone, 23 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 50 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.

Following a +7.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 50-day moving average for XRAY moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XRAY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.402) is normal, around the industry mean (4.961). P/E Ratio (-3.480) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.067) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.